A study in the journal The Lancet Oncology reports that when the drugs Herceptin and Tykerb join forces they significantly reduce breast cancer tumor size.
Women with HER2 positive breast cancer were treated with the combo. After six weeks, those patients had tumors twenty percent smaller than women taking either drug alone.
Herceptin is already approved for breast cancer and Tyker has been used for advanced cancer. This is the first time they have been tested together.